Rankl Mcsf Differentiation
Rankl Mcsf Differentiation - Related Videos
10:21
Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells
0 Views •
Cited by 3 •
2018
Here detailed protocols for culturing the murine myeloid precursor 32D/G-CSF-R cell line, performing viral infections, and carrying out proliferation and differentiation assays are presented. This cell line is suitable for studying myeloid cell development, and the role of genes of interest in myeloid cell growth and neutrophilic differentiation.
07:01
An In Vitro Technique to Differentiate GM-CSF Producing T Helper Cells from Naïve T Cells
0 Views •
2025
This video demonstrates the in vitro differentiation of granulocyte-macrophage-colony-stimulating factor or GM-CSF-producing T helper cells (THGM). Isolated naïve T cells are stimulated for differentiation into THGM, which is confirmed by detecting high intracellular GM-CSF production and a low expression of other T helper cell-specific cytokines.
07:45
A Cell Free Assay System Estimating the Neutralizing Capacity of GM-CSF Antibody using Recombinant Soluble GM-CSF Receptor
0 Views •
2011
We designed a cell-free receptor binding assay in order to estimate the binding of granulocyte-macrophage colony-stimulating factor (GM-CSF) to the receptors. It enables us to evaluate competitive inhibition of biotinylated GM-CSF binding to soluble GM-CSF receptor alpha by GM-CSF autoantibody with excellent reproducibility.
07:08
A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status
0 Views •
Cited by 3 •
2016
We describe a high-throughput, multiplex, and targeted proteomic cerebrospinal fluid (CSF) assay developed with potential for clinical translation. The test can quantitate potential markers and risk factors for neurodegeneration, such as the apolipoprotein E variants (E2, E3 and E4), and measure their allelic expression.
10:27
In Vitro Differentiation of Mouse Granulocyte-macrophage-colony-stimulating Factor (GM-CSF)-producing T Helper (THGM) Cells
0 Views •
Cited by 1 •
2018
Here, we present a protocol to differentiate murine granulocyte-macrophage-colony-stimulating-factor-producing T helper (THGM) cells from naive CD4+ T cells, including isolation of naive CD4+ T cells, differentiation of THGM, and analysis of differentiated THGM cells. This method can be applied to studies of the regulation and function of THGM cells.
FAQs
M-CSF primarily supports the survival and proliferation of monocyte or macrophage precursors before they undergo full osteoclast development. This stage expands and maintains the responding cell population, making it possible to examine how subsequent RANKL exposure changes differentiation rather than simply reflecting precursor loss. M-CSF therefore establishes the cellular foundation for the model.
RANKL activates RANK signaling in precursor cells, leading to NF-κB and NFATc1 activity. These transcriptional regulators, meaning proteins that control gene expression, promote the osteoclast-specific program. The resulting molecular changes coordinate differentiation, cell fusion, and multinucleation, linking receptor stimulation to the formation of mature bone-resorbing cells.
NFATc1 functions as a central transcriptional driver downstream of RANKL signaling. Its activity helps convert precursor responses into the gene-expression changes associated with osteoclast maturation, rather than leaving cells in an undifferentiated state. Monitoring this pathway can help researchers connect altered signaling with defects or enhancements in fusion and multinucleated osteoclast formation.
The system controls the signals presented to monocyte or macrophage precursors by using M-CSF to support the precursor population and RANKL to activate osteoclast differentiation. This controlled combination allows investigators to attribute developmental changes to the relevant growth or differentiation signal. It is especially useful when comparing pathway perturbations or candidate interventions under consistent in vitro conditions.
Because the culture system provides a controlled setting for osteoclast development, it helps researchers examine mechanisms that enhance pathological osteoclast activation. Cancer researchers can use the resulting cells to study processes connected with bone metastasis and cancer-associated bone destruction, while relating those effects to the RANKL-RANK signaling axis and its influence on bone-resorbing cell formation.
These cultures support evaluation of molecular pathways and therapies intended to reduce pathological bone resorption. In particular, they can help assess strategies that target the RANKL-RANK axis and determine whether pathway modulation alters osteoclast development. The model therefore connects mechanistic signaling studies with cancer-relevant questions about limiting bone damage associated with metastatic or tumor-driven disease.